Trending Now
Business
Endo: More Fireworks Ahead
Endo Pharmaceuticals (ENDP) delivered a Q2 revenue and earnings beat last week, and the fireworks flew. ENDP rose as much s 38% on the...
Why Mallinckrodt Cratered
Mallinckrodt (MNK) reported FQ3 revenue of $794 million and eps of $1.97. The company missed on revenue, but its stagnant growth in its main...
Lifestyle today
Entertainment
Fitch Downgrades Teva To Junk Status
I previously wondered who would downgrade Teva (TEVA) first? Moody's or S&P? Monday Fitch beat them to it, downgrading the generics giant to junk...
Endo To Appeal Non-Infringement Ruling In Vasostrict Patent Litigation
Former president Donald Trump was highly critical of opioid drug manufacturers. He wanted to shed more light on their role in the...
Xiaflex Test
Live Stream Details
//player.dacast.com/js/player.js
Twitter Share
https://iframe.dacast.com/b/94015/c/484752
Facebook Share Code
https://iframe.dacast.com/b/94015/c/484752
Trump And The Global Economy ("Trump And The GE") featuring Missouri Representative Maria Chappelle-Nadal and Professor Lance Brofman was...
CSX Sticks With Harrison’s Plan To Cut Jobs, Reduce Trains
CSX (CSX) recently affirmed it would stick with former CEO Hunter Harrison's plan to cut jobs and rail cars, and slash capital spending:
U.S. railroad...
Trump And The Global Economy Explains Folly of Trump’s Trade War
In early March President Trump announced tariffs on steel and aluminum from China and South Korea who purportedly flood the U.S. market with the...
Drug Overdose Deaths Rise 30% To Record Levels
The U.S. is in the midst of an opioid crisis. In 2017 President Trump acknowledged the opioid crisis and the roles played...
40 Celebrities Who DGAF About Cellulite: #40 Tom Cruise
In the social media people are constantly trying to look better and project a positive image to the public. There are hundreds of billions...
Allergan: RegenerX’s Stellar Phase 3 Ushers In Another Dry Eye Competitor
The results of RegenerX's phase clinical trials pursuant to dry are in and the company passed with flying colors. Its ARISE-2 trial investigated RGN-259's...























































































































